A5083562890- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Animal Virus Infections Studies
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 detection and testing
- Intensive Care Unit Cognitive Disorders
- Dental Research and COVID-19
- HIV Research and Treatment
- COVID-19 and Mental Health
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Infection Control and Ventilation
- Respiratory Support and Mechanisms
- Vitamin C and Antioxidants Research
- Geophysical Methods and Applications
- Influenza Virus Research Studies
- Microwave Imaging and Scattering Analysis
- Respiratory viral infections research
- Frailty in Older Adults
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- COVID-19 impact on air quality
- Public Administration and Political Analysis
- Neonatal Respiratory Health Research
- Virus-based gene therapy research
Queen's Medical Centre
2020-2024
University of Nottingham
2020-2024
University of London
2024
London School of Hygiene & Tropical Medicine
2024
University of Connecticut
2024
University of Leicester
2023
University Hospitals of Leicester NHS Trust
2023
NIHR Southampton Biomedical Research Centre
2023
University of Oxford
2023
National Institute for Health Research
2023
Outbreaks of emerging infections present health professionals with the unique challenge trying to select appropriate pharmacologic treatments in clinic little time available for drug testing and development. Typically, clinicians are left general supportive care often untested convalescent-phase plasma as treatment options. Repurposing approved pharmaceutical drugs new indications presents an attractive alternative clinicians, researchers, public agencies, developers, funding agencies. Given...
Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 Saudi Arabia and has caused over 2400 cases more than 800 deaths. Epidemiological studies identified diabetes as the primary comorbidity associated with severe or lethal MERS-CoV infection. Understanding how affects MERS is important because of global burden pandemic potential MERS-CoV. We used a model which mice were made susceptible to by expressing human DPP4, type 2 was induced administering high-fat diet. Upon...
The highly pathogenic severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East (MERS-CoV) cause significant morbidity morality. There is currently no approved therapeutic for coronaviruses, even as MERS-CoV spreading throughout the East. We previously screened a library of FDA-approved drugs inhibitors replication in which we identified Abelson (Abl) kinase inhibitors, including anticancer drug imatinib, both SARS-CoV vitro Here show that anti-CoV activity imatinib occurs at...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China at the end of 2019 and has rapidly caused a pandemic, with over 20 million recorded COVID-19 cases August 2020 (https://covid19.who.int/). There are no FDA-approved antivirals or vaccines for any coronavirus, including SARS-CoV-2. Current treatments limited to supportive therapies off-label use drugs. Rapid development human testing potential is urgently needed. Numerous drugs already approved use, subsequently,...
Traditional approaches to antimicrobial drug development are poorly suited combatting the emergence of novel pathogens. Additionally, lack small animal models for these infections hinders in vivo testing potential therapeutics. Here we demonstrate use VelocImmune technology (a mouse that expresses human antibody-variable heavy chains and κ light chains) alongside VelociGene (which allows rapid engineering genome) quickly develop evaluate antibodies against an emerging viral disease....
Rationale: Shared symptoms and genetic architecture between coronavirus disease (COVID-19) lung fibrosis suggest severe acute respiratory syndrome 2 (SARS-CoV-2) infection may lead to progressive damage. Objectives: The UK Interstitial Lung Disease Consortium (UKILD) post–COVID-19 study interim analysis was planned estimate the prevalence of residual abnormalities in people hospitalized with COVID-19 on basis risk strata. Methods: PHOSP–COVID-19 (Post-Hospitalization COVID-19) used capture...
Abstract Background SAMHD1 is an HIV-1 restriction factor in non-dividing monocytes, dendritic cells (DCs), macrophages, and resting CD4 + T-cells. Acting as a deoxynucleoside triphosphate (dNTP) triphosphohydrolase, hydrolyzes dNTPs restricts infection macrophages T-cells by decreasing the intracellular dNTP pool. However, pool DCs its regulation remain unclear. has been reported type I interferon (IFN)-inducible protein, but whether IFNs upregulate expression primary T-lymphocytes unknown....
Severe acute respiratory syndrome (SARS) emerged in November 2002 as a case of atypical pneumonia China, and the causative agent SARS was identified to be novel coronavirus, severe coronavirus (SARS-CoV). Bone marrow stromal antigen 2 (BST-2; also known CD317 or tetherin) initially pre-B-cell growth promoter, but it inhibits release virions retrovirus human immunodeficiency virus type 1 (HIV-1) by tethering budding host cell membrane. Further work has shown that BST-2 restricts many other...
The Middle East respiratory syndrome coronavirus (MERS-CoV) is a newly emerging highly pathogenic virus causing almost 50 % lethality in infected individuals. development of small-animal model critical for the understanding this and to aid countermeasures against MERS-CoV. We found that BALB/c, 129/SvEv STAT1 knockout mice are not permissive MERS-CoV infection. lack infection may be due low level mRNA protein receptor, dipeptidyl peptidase 4 (DPP4), lungs mice. DPP4 likely contributes viral...
We have previously shown that SSYA10-001 blocks severe acute respiratory syndrome coronavirus (SARS-CoV) replication by inhibiting SARS-CoV helicase (nsp13). Here, we show also inhibits of two other coronaviruses, mouse hepatitis virus (MHV) and Middle Eastern (MERS-CoV). A putative binding pocket for was identified to be similar in SARS-CoV, MERS-CoV, MHV helicases. These studies it is possible target multiple coronaviruses through broad-spectrum inhibitors.
Anti–MERS-CoV human IgG produced from transchromosomic bovines neutralizes MERS-CoV in vitro and vivo.
ABSTRACT Severe acute respiratory syndrome coronavirus (SARS-CoV) is a highly pathogenic virus that causes morbidity and mortality in humans. After infection with SARS-CoV, the lung injury caused by must be repaired to regain function. A dysregulation this wound healing process leads fibrosis. Many survivors of SARS-CoV develop pulmonary fibrosis (PF), higher prevalence older patients. Using mouse models pathogenesis, we have identified repair pathway, controlled epidermal growth factor...
The recently emerged Middle East respiratory syndrome coronavirus (MERS-CoV), a betacoronavirus, is associated with severe pneumonia and renal failure. environmental origin of MERS-CoV as yet unknown; however, its genome sequence closely related to those two bat coronaviruses, named BtCoV-HKU4 BtCoV-HKU5, which were derived from Chinese samples. A hallmark highly pathogenic viruses their ability evade the innate immune response host. CoV accessory proteins, for example acute (SARS-CoV), have...
Abstract SARS-CoV-2 emerged in China at the end of 2019 and has rapidly become a pandemic with roughly 2.7 million recorded COVID-19 cases greater than 189,000 deaths by April 23rd, 2020 ( www.WHO.org ). There are no FDA approved antivirals or vaccines for any coronavirus, including SARS-CoV-2. Current treatments limited to supportive therapies off-label use drugs. Rapid development human testing potential is greatly needed. A quick way test compounds antiviral activity through drug...
Through-lossy-slab radar imaging will be shown at stand-off ranges using a low-power, ultrawideband (UWB), frequency modulated continuous wave (FMCW) system. FMCW is desirable for through-slab applications because of the signal gain resulting from pulse compression long transmit pulses (1.926-4.069 GHz chirp in 10 ms). The difficulty utilizing this application that air-slab boundary dominates scattered return target scene and limits upper bound receiver dynamic range, reducing sensitivity...
Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and is a highly pathogenic virus. There are no treatment options against MERS-CoV for humans or animals, there large-scale clinical trials therapies MERS-CoV. To address this need, we developed an inactivated rabies virus (RABV) that contains the spike (S) protein expressed on its surface. Our initial recombinant vaccine, BNSP333-S, expresses full-length wild-type S protein; however, it showed significantly reduced viral...
Abstract Middle East respiratory syndrome coronavirus (MERS‐CoV) is an emerging highly pathogenic virus. Although MERS‐CoV only emerged in 2012, we and others have developed assays to grow quantify infectious RNA products of replication vitro. able infect a range cell types, but replicates high titers Vero E6 cells. Protocols for the propagation quantification are presented. © 2015 by John Wiley & Sons, Inc.
ABSTRACT Middle East respiratory syndrome coronavirus (MERS-CoV) is an important emerging pathogen that was first described in 2012. While the cell surface receptor for MERS-CoV has been identified as dipeptidyl peptidase 4 (DPP4), mouse DPP4 homologue does not allow virus entry into cells. Therefore, development of models hampered by fact replicate commonly available strains. We have previously a model which mDPP4 replaced with hDPP4 such expressed under endogenous promoter. In this study,...
There is an urgent need for drugs, therapies and vaccines to be available protect the human population against COVID-19. One of first approaches taken in COVID-19 global response was consider repurposing licensed drugs. This commentary highlights extraordinary international collaborative effort independent researchers who have recently all come same conclusion—that chloroquine or hydroxchloroquine are unlikely provide clinical benefit
There has been limited characterisation of bat-borne coronaviruses in Europe. Here, we screened for 48 faecal samples from 16 the 17 bat species breeding UK, collected through a rehabilitation and conservationist network. We recovered nine complete genomes, including two novel coronavirus species, across six species: four alphacoronaviruses, MERS-related betacoronavirus, closely related sarbecoviruses. demonstrate that at least one these sarbecoviruses can bind use human ACE2 receptor...